Accrual Monitoring and Intervention
Most clinical trial enrollment problems are not sudden failures — they're gradual drifts that become crises because they weren't caught early. A trial that will miss its enrollment target by 30% at the end of the enrollment period usually showed the signal six months in.
The challenge is detection: traditional enrollment monitoring is backward-looking (we enrolled X patients last month) rather than predictive (we are on track to enroll Y patients by the deadline). By the time the problem is obvious, intervention options are limited and expensive.
The predictive accrual model
A well-designed accrual monitoring system does three things:
1. Maintains a running enrollment forecast. Based on current enrollment velocity, site-level performance, and historical patterns for similar trials, it projects when the enrollment target will be met under current conditions — and what that date means for the program timeline.
2. Identifies underperforming sites early. A site that was expected to enroll 2 patients per month and has enrolled 0 in month two needs attention in month three, not month eight. AI monitoring flags site deviations from projected performance immediately.
3. Generates intervention recommendations. Not all enrollment problems have the same fix. A site with high screen failure rates needs protocol eligibility analysis. A site with low referrals needs patient identification support. A site that's activated but not enrolling needs site management attention. The system routes each problem to the appropriate response.
The intervention menu
When enrollment falls behind, the available interventions are well-understood:
- Site activation: Add new sites. The fastest option but takes 3-4 months to impact enrollment.
- Protocol amendment: Liberalize restrictive eligibility criteria. High-impact but regulatory timeline dependent.
- Referral support: Active outreach to referring physicians and patient communities at underperforming sites.
- Screen failure analysis: Identify and address the most common failure criteria.
- Competitive trial monitoring: If a competitor trial is recruiting the same patients, adjust your outreach strategy.
The value of early detection is that you have access to the full intervention menu. Detect the problem in month three and all five options are available. Detect it in month twelve and you're down to site activation — the slowest option.
Early warning, enabled by AI monitoring, is the leverage point.